GSA Capital Partners’s AbbVie ABBV Stock Holding History

GSA Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,116	Closed	-$1.11M	–	1696
2026 Q1	$1.11M	Buy	+5,116	New	+$1.13M	0.07%	431
2025 Q3	–	Sell	-19,293	Closed	-$3.58M	–	1599
2025 Q2	$3.58M	Buy	19,293 +10,441	+118%	+$1.94M	0.25%	31
2025 Q1	$1.85M	Buy	8,852 +6,050	+216%	+$1.18M	0.17%	84
2024 Q4	$498K	Buy	+2,802	New	+$515K	0.04%	890
2024 Q2	–	Sell	-2,965	Closed	-$540K	–	1579
2024 Q1	$540K	Sell	2,965 -3,696	-55%	-$637K	0.04%	829
2023 Q4	$1.03M	Buy	+6,661	New	+$971K	0.09%	377
2023 Q3	–	Sell	-7,876	Closed	-$1.06M	–	1440
2023 Q2	$1.06M	Buy	+7,876	New	+$1.15M	0.11%	270
2022 Q3	–	Sell	-1,491	Closed	-$228K	–	1462
2022 Q2	$228K	Buy	+1,491	New	+$228K	0.03%	1003
2021 Q3	–	Sell	-3,675	Closed	-$414K	–	1366
2021 Q2	$414K	Buy	+3,675	New	+$414K	0.05%	747
2020 Q4	–	Sell	-2,840	Closed	-$249K	–	1153
2020 Q3	$249K	Buy	+2,840	New	+$267K	0.04%	865
2020 Q2	–	Sell	-5,122	Closed	-$390K	–	575
2020 Q1	$390K	Sell	5,122 -11,305	-69%	-$963K	0.1%	300
2019 Q4	$1.45M	Buy	16,427 +12,427	+311%	+$1.03M	0.17%	79
2019 Q3	$303K	Sell	4,000 -29,568	-88%	-$2.03M	0.04%	885
2019 Q2	$2.44M	Buy	+33,568	New	+$2.64M	0.27%	22
2018 Q4	–	Sell	-11,600	Closed	-$1.1M	–	1298
2018 Q3	$1.1M	Sell	11,600 -1,042	-8%	-$98.8K	0.06%	628
2018 Q2	$1.17M	Sell	12,642 -44,366	-78%	-$4.33M	0.06%	645
2018 Q1	$5.4M	Buy	+57,008	New	+$6.26M	0.29%	19
2017 Q4	–	Sell	-3,168	Closed	-$282K	–	1523
2017 Q3	$282K	Sell	3,168 -49	-2%	-$3.73K	0.02%	1282
2017 Q2	$233K	Buy	+3,217	New	+$216K	0.02%	1442
2016 Q4	–	Sell	-20,659	Closed	-$1.3M	–	1716
2016 Q3	$1.3M	Buy	+20,659	New	+$1.34M	0.07%	457
2016 Q2	–	Sell	-9,412	Closed	-$538K	–	1707
2016 Q1	$538K	Sell	9,412 -15,325	-62%	-$854K	0.03%	967
2015 Q4	$1.47M	Sell	24,737 -266,977	-92%	-$15.4M	0.07%	440
2015 Q3	$15.9M	Buy	291,714 +245,495	+531%	+$16M	0.78%	4
2015 Q2	$3.1M	Sell	46,219 -18,272	-28%	-$1.19M	0.12%	161
2015 Q1	$3.77M	Sell	64,491 -26,485	-29%	-$1.6M	0.15%	98
2014 Q4	$5.95M	Buy	90,976 +70,868	+352%	+$4.47M	0.42%	9
2014 Q3	$1.16M	Buy	+20,108	New	+$1.12M	0.06%	404
2014 Q2	–	Sell	-19,552	Closed	-$1M	–	1773
2014 Q1	$1M	Buy	19,552 +4,499	+30%	+$227K	0.07%	332
2013 Q4	$795K	Sell	15,053 -5,151	-25%	-$253K	0.06%	504
2013 Q3	$904K	Buy	20,204 +14,901	+281%	+$661K	0.07%	403
2013 Q2	$219K	Buy	+5,303	New	+$232K	0.03%	1039

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

GSA Capital Partners's ABBV Position: Q2 2026 in Review

GSA Capital Partners sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 5,116 shares — an estimated $1.11M sold.

GSA Capital Partners first reported a position in ABBV in Q2 2013 and held it in 31 quarters. The position peaked at $15.9M in Q3 2015. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

GSA Capital Partners reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
GSA Capital Partners sold 5,116 AbbVie shares in Q2 2026, an estimated $1.11M.
GSA Capital Partners first reported a position in AbbVie in Q2 2013 and held it in 31 quarters.
GSA Capital Partners's AbbVie position peaked at $15.9M in Q3 2015.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.